Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2478
Real-time Quote. Real-time Tradegate - 10/24 02:44:09 pm
85.001 EUR   +0.12%
39m ago Exclusive - Unipharm hires Houlihan Lokey to explore $500 million sale -..
49m agoDJFlu-Shot Supply Dented by Production Woes
1h agoDJFlu-Shot Supply Dented by Production Woes
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

02/22/2013 | 07:58am US/Eastern

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Latest news on SANOFI
39m ago Exclusive - Unipharm hires Houlihan Lokey to explore $500 million sale -sourc..
49m agoDJFlu-Shot Supply Dented by Production Woes
1h agoDJFlu-Shot Supply Dented by Production Woes
1h ago GENZYME : BioMarin Announces Third Quarter 2014 Financial Results
9h agoDJSanofi SA 3Q 2014-- Forecast
9h ago SANOFI : Information concerning the total number of voting rights and shares
1d ago GENZYME : iTraumaCare Positions New Leader for Next-Level Growth
1d agoSANOFI SA : quaterly earnings release
1d ago SANOFI : Restates Commitment to Wellness in Nigeria
1d ago GENZYME : Reports Results from Two Phase III Studies
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF